| |
[摘要]：Background: A growing number of patent applications on dopamine (DA) D-3 receptors have been filed over the last 10 years. The increased interest in this target correlates with evidence that implicates the DA D-3 receptor in the control of drug-seeking behavior and in the pathophysiology of some impulse control disorders and schizophrenia. Objectives: This manuscript provides an overview of the most recent literature in support of the biologic rationale for the use of selective DA D-3 receptor antagonists for neuropsychiatric indications, and reviews > 80 patents that reflect 10-year advances in the discovery of these compounds by pharmaceutical companies, national research institutes and academic groups. Methods: Analysis of > 100 primary literature and 80 patent references of the last 10 years. Conclusions: The recent synthesis and profiling of new highly potent and selective DA D-3 receptor antagonists over the last 10 years has permitted the testing of these compounds in a wide range of preclinical animal models of neuropsychiatric diseases. Clinical trials have now been initiated and clinical proof-of-concept is expected in the forthcoming years. |
|
